Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy.

× No keyword cloud information.

29 in total

1. Immuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualized.

Authors: Hu Liu; Shuang Geng; Bo Wang; Bing Wu; Xiaoping Xie; Shuang Wang; Yiwei Zhong; Xuanyi Wang; Di Qu; Yumei Wen; Bin Wang
Journal: Hum Vaccin Immunother Date: 2016 Impact factor: 3.452

Review 2. New therapeutic vaccination strategies for the treatment of chronic hepatitis B.

Authors: Jia Liu; Anna Kosinska; Mengji Lu; Michael Roggendorf
Journal: Virol Sin Date: 2014-01-17 Impact factor: 4.327

3. Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.

Authors: Chenliang Zhou; Chaofan Li; Guo-Zhong Gong; Shuang Wang; Ji-Ming Zhang; Dao-Zhen Xu; Li-Min Guo; Hong Ren; Min Xu; Qing Xie; Chen Pan; Jie Xu; Zhongyu Hu; Shuang Geng; Xian Zhou; Xianzheng Wang; Xiaoyu Zhou; Haili Mi; Gan Zhao; Wencong Yu; Yu-Mei Wen; Lihua Huang; Xuan-Yi Wang; Bin Wang
Journal: Hum Vaccin Immunother Date: 2017-06-30 Impact factor: 3.452

Review 4. Designing immune therapy for chronic hepatitis B.

Authors: Sheikh Mohammad Fazle Akbar; Mamun Al-Mahtab; Yoichi Hiasa
Journal: J Clin Exp Hepatol Date: 2014-06-26

5. Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier.

Authors: S K Akbar; N Horiike; M Onji
Journal: Immunology Date: 1999-01 Impact factor: 7.397

6. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells.

Authors: K Kurose; S M Akbar; K Yamamoto; M Onji
Journal: Immunology Date: 1997-12 Impact factor: 7.397

7. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors: Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal: Antimicrob Agents Chemother Date: 2009-09-21 Impact factor: 5.191

Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy.